SBFM
Sunshine Biopharma Inc.
-0.11 (-10.67%)0.92USD202K成交股數3.6M市值0.0本益比(近四季)0.1股價營收比-1.6%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 9.3M-2% | 8.1M-9% | 8.6M+2% | 9.4M+1% | 9.4M+25% | 8.9M+16% | 8.4M+42% | 9.3M+67% | 7.5M | 7.7M | 6.0M | 5.6M |
| 營業成本 | 6.8M | 5.9M | 5.5M | 6.3M | 6.0M | 6.2M | 5.6M | 6.9M | 5.2M | 5.1M | 4.0M | 3.6M |
| 毛利 | 2.4M-29% | 2.2M-20% | 3.0M+6% | 3.1M+30% | 3.4M+45% | 2.7M+6% | 2.9M+44% | 2.4M+21% | 2.4M | 2.6M | 2.0M | 2.0M |
| 毛利率 | 26.2% | 27.0% | 35.3% | 32.6% | 36.4% | 30.7% | 34.0% | 25.3% | 31.2% | 33.4% | 33.4% | 35.1% |
| 研發費用 | 13K | 32K | 74K | 119K | 196K | 215K | 126K | 436K | 222K | 816K | 238K | 369K |
| 銷售管理費用 | 4.0M | 3.6M | 4.8M | 4.2M | 5.5M | 4.0M | 4.0M | 3.6M | 3.7M | 3.7M | 2.8M | 3.0M |
| 營業利益 | −1.6M-22% | −1.4M+8% | −1.8M+62% | −1.1M-14% | −2.1M+52% | −1.3M+11% | −1.1M+42% | −1.3M+25% | −1.4M | −1.2M | −779K | −1.0M |
| 營業利益率 | -17.4% | -17.3% | -20.9% | -11.5% | -21.8% | -14.6% | -13.1% | -13.6% | -17.9% | -15.1% | -13.1% | -18.2% |
| 稅後淨利 | −1.6M-12% | −1.2M+5% | −2.1M+79% | −884K+79% | −1.8M+38% | −1.2M-6% | −1.2M+84% | −494K-45% | −1.3M | −1.3M | −651K | −902K |
| 淨利率 | -16.9% | -15.4% | -25.0% | -9.4% | -18.8% | -13.3% | -14.2% | -5.3% | -17.0% | -16.3% | -10.9% | -16.2% |
| 稀釋 EPS | – | – | – | – | -0.82-59% | -0.44 | – | -43.48 | -2.00 | – | – | – |
| 稀釋股數 | – | – | – | – | 3.6M | 2.7M | 1.3M | 40.9K | 641K | 12.8K | 12.8K | 12.7K |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 13.7M | 6.9M | 9.1M | 9.3M | 10.3M | 8.1M | 12.2M | 11.5M | 17.4M | 16.3M | 18.8M | 19.7M |
| 應收帳款 | 4.0M | 4.0M | 3.5M | 4.2M | 3.6M | 3.4M | 3.2M | 4.0M | 2.8M | 2.6M | 2.0M | 2.0M |
| 存貨 | 12.1M | 13.2M | 13.5M | 14.1M | 13.0M | 11.9M | 9.8M | 8.5M | 7.7M | 5.7M | 4.5M | 4.3M |
| 總資產 | 33.6M | 27.9M | 30.1M | 31.5M | 32.0M | 29.2M | 30.1M | 29.3M | 31.9M | 27.3M | 27.7M | 28.4M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 6.1M | 6.4M | 7.0M | 7.3M | 6.3M | 6.5M | 5.0M | 5.8M | 7.1M | 6.1M | 5.7M | 5.3M |
| 股東權益 | 27.5M | 21.5M | 23.0M | 24.2M | 25.7M | 22.7M | 25.0M | 23.5M | 24.8M | 21.2M | 22.0M | 23.1M |
| 負債比 | 18.1% | 23.0% | 23.4% | 23.1% | 19.6% | 22.2% | 16.7% | 19.8% | 22.2% | 22.5% | 20.6% | 18.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.1M+22% | – | – | – | −1.7M | – | – | −3.2M | – | – | – |
| 資本支出 | – | 5K | – | – | – | 7K | – | – | 63K | – | – | – |
| 自由現金流 | – | −2.1M+22% | – | – | – | −1.7M | – | – | −3.2M | – | – | – |
| 折舊攤銷 | 78K | 77K | – | – | 73K | 65K | – | – | 43K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | 0.00 | – | – | 3.1M | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -25.7% | – | – | – | -19.1% | – | – | -43.1% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 36.3M | +4.1% | −6.0M | -16.5% | – | −5.5M |
| FY2024 | 34.9M | +44.7% | −5.1M | -14.7% | -7.32 | −14.2M |
| FY2023 | 24.1M | +454.4% | −4.5M | -18.7% | -351.36 | −8.9M |
| FY2022 | 4.3M | +1802.4% | −26.7M | -615.4% | -1.76 | −5.4M |
| FY2021 | 228K | +219.9% | −12.4M | -5,444.4% | -4.76 | −1.8M |
| FY2020 | 71K | +238.1% | −2.8M | -3,898.7% | – | −658K |
| FY2019 | 21K | – | −1.7M | -7,860.9% | – | −497K |
| FY2018 | 0.00 | – | −2.2M | –% | – | −532K |